Login to Your Account

FDA Wants More Info

ViroPharma to Start 'At-Risk' Cinryze Manufacturing in 1Q11

By Tom Wall

Monday, October 25, 2010
Industrial-scale manufacturing of Cinryze (C1-esterase inhibitor, human) will stay on schedule despite an FDA complete response letter requesting additional information about the expansion, according to ViroPharma Inc.'s President and CEO Vincent Milano. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription